SR9009 is a REV-ERB agonist that increases the constitutive repression of genes regulated by REV-ERB α (IC50=670 nM) and REV-ERBβ (IC50 = 800 nM). SR9009 decreases the circadian locomotor activity during dark phase through activation of REV-ERB, altering the expression pattern of core clock genes in the hypothalamai of mice. In in vivo experiments SR9009 has shown to decrease body fat and improved dyslipidemia and hyperglycemia. MW: 437.94. Purity ≥98% by HPLC